Ischemic heart disease Board decisions

The Board granted service connection for coronary artery disease (CAD) and diabetes mellitus type II, finding that the Veteran's CAD is secondary to his now-service-connected diabetes and that his obesity, which was aggravated by other service-connected conditions, resulted in his diabetes.

The Board remands the claims for service connection for a heart condition and the cause of the Veteran's death due to a pre-decisional duty to assist error related to the Veteran's exposure to ionizing radiation and/or asbestos in service.

The Board granted service connection for GERD, and remanded the other issues for further development.

The Board remands the claims for a heart disability and an acquired psychiatric disorder to correct pre-decisional duty to assist errors, including obtaining better quality copies of service records and providing VA examinations.

The Board remands the issues of service connection for a heart disability, left ankle disability, and TDIU due to pre-decisional duty to assist errors.

The Board granted service connection for a heart disability, claimed as CAD and left lower extremity peripheral neuropathy (LLE PN) under the PACT Act. However, it remanded the claims for right lower extremity peripheral neuropathy (RLE PN), left upper extremity peripheral neuropathy (LUE PN), and right upper extremity peripheral neuropathy (RUE PN) due to pre-decisional error.

The Board granted service connection for hypertension, diabetes mellitus, type II (DM), residuals of a stroke, and atherosclerotic heart disease, arteriosclerotic heart disease (coronary artery disease (CAD)), heart block, and coronary artery bypass graft (CABG) based on the evidence showing that these conditions are related to the Veteran's military service.

The Board dismissed the appeals for service connection for cystic kidney disease and heart disease, as well as denied a rating in excess of 20 percent for prostate cancer.

The Veteran's psychiatric disability, CAD, and bladder cancer residuals were rated at various levels based on the severity of symptoms during different periods.

The Board remands the appeal for the AOJ to properly consider and adjudicate the Veteran's motion for clear and unmistakable error (CUE) regarding a May 2013 rating decision that denied service connection for ischemic heart disease.

The Board remands the claims for service connection for respiratory, heart, and pulmonary hypertension disabilities to correct duty to assist errors.

The Board denied the Veteran's claims for service connection for diabetes mellitus, type 2 and a heart disorder, both claimed as due to herbicide agent exposure.

The Board granted service connection for coronary artery disease and hypertension, finding that these conditions are causally related to the Veteran's active service.

The Board dismissed the veteran's appeal for service connection for heart disability, prostate cancer, diabetes mellitus, type II, and peripheral neuropathy due to a lack of jurisdiction.

The Board denied the veteran's claims for service connection for a right foot condition, left foot condition, heart condition, and restless leg syndrome as there was no evidence to support that these conditions were related to his active military service.

The Board denied an initial evaluation higher than 10 percent for ischemic heart disease and a rating higher than 50 percent for PTSD, but granted a 50 percent rating prior to September 23, 2020.

The appeal was dismissed due to the Veteran's death during its pendency.

The Board denied the Veteran's claims for compensation under 38 U.S.C. § 1151 for various disabilities, including a right shoulder disability and conditions secondary to it, as there was no evidence that VA treatment caused additional disability beyond what would have occurred due to pre-existing conditions.

The Board granted an effective date of July 2, 2019, for the grant of service connection for hypertension and a rating of 10 percent for hypertension. Other claims were denied.

The Board denied the veteran's claims for increased ratings for ischemic heart disease, chronic kidney disease, and diabetes mellitus type II.